ArticleBritish journal of clinical pharmacology2020

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.

Devalingam Mahalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.